I asked for an update on the N-Assay work. Apparently, others have been asking since I received the following which has been used as a response to others and now to me:
"The customization is progressing and on track. The bacteria that are the customization targets do not have off the shelf antibodies available so the process is longer than if antibodies were in stock. For insight, that process is as follows: we obtained the bacteria from ATCC, which is essentially the national repository for bacteria. We then have to reconstitute that bacteria, culture it to establish it's viable, then kill it to place it in a condition that allows only dead proteins to remain in order to conform to the requirements of the large labs that generate antibodies. We did all of that and then chose one of two courses of production for the antibodies--- those available are a 70-day or a 90-day antibody growth process. The 90-day provides a better end product, so rather than skimping and then discovering the 70-day wasn't the best choice, we naturally went with the longer course.
We're somewhere past halfway in their development. After the antibodies are developed then we take a portion of those and conjugate them to generate secondary antibodies. When the paper is published we can reveal how those are used. That segues into your second question: the paper is in the hands of the editors of a prominent peer reviewed journal. We have no influence over any decisions they make, so we're waiting."
"The customization is progressing and on track. The bacteria that are the customization targets do not have off the shelf antibodies available so the process is longer than if antibodies were in stock. For insight, that process is as follows: we obtained the bacteria from ATCC, which is essentially the national repository for bacteria. We then have to reconstitute that bacteria, culture it to establish it's viable, then kill it to place it in a condition that allows only dead proteins to remain in order to conform to the requirements of the large labs that generate antibodies. We did all of that and then chose one of two courses of production for the antibodies--- those available are a 70-day or a 90-day antibody growth process. The 90-day provides a better end product, so rather than skimping and then discovering the 70-day wasn't the best choice, we naturally went with the longer course.
We're somewhere past halfway in their development. After the antibodies are developed then we take a portion of those and conjugate them to generate secondary antibodies. When the paper is published we can reveal how those are used. That segues into your second question: the paper is in the hands of the editors of a prominent peer reviewed journal. We have no influence over any decisions they make, so we're waiting."
13
1
